Considerations regarding an updated meta-analysis of the optimal duration of oxaliplatin-based adjuvant chemotherapy in patients with different risk factors for stage II-III colon cancer

被引：0
|
作者：
Pang, Huayang [1 ,2 ]
Yan, Menghua [1 ]
Chen, Lihui [1 ]
Zhao, Zhou [1 ,2 ]
Li, Wei [1 ]
Zhang, Shouru [1 ]
Sun, Hao [1 ]
机构：
[1] Chongqing Univ Canc Hosp, Dept Gastrointestinal Canc Ctr, Chongqing 400030, Peoples R China
[2] Chongqing Univ Canc Hosp, Chongqing Key Lab Translat Res Canc Metastasis & I, Chongqing, Peoples R China
来源：
INTERNATIONAL JOURNAL OF SURGERY | 2024年 / 110卷 / 07期
关键词：
FLUOROPYRIMIDINE; THERAPY;
D O I：
10.1097/JS9.0000000000001350
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：4431 / 4432
页数：2
相关论文
共 50 条
  • [21] Administration of adjuvant chemotherapy for stage II-III colon cancer patients: An European population-based study
    Babaei, Masoud
    Balavarca, Yesilda
    Jansen, Lina
    Lemmens, Valery
    van Erning, Felice N.
    van Eycken, Liesbet
    Vaes, Evelien
    Sjovall, Annika
    Glimelius, Bengt
    Ulrich, Cornelia M.
    Schrotz-King, Petra
    Brenner, Hermann
    INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (07) : 1480 - 1489
  • [22] Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial
    Yamazaki, K.
    Yamanaka, T.
    Shiozawa, M.
    Manaka, D.
    Kotaka, M.
    Gamoh, M.
    Shiomi, A.
    Makiyama, A.
    Munemoto, Y.
    Rikiyama, T.
    Fukunaga, M.
    Ueki, T.
    Shitara, K.
    Shinkai, H.
    Tanida, N.
    Oki, E.
    Sunami, E.
    Ohtsu, A.
    Maehara, Y.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2021, 32 (01) : 77 - 84
  • [23] Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (CC): Updated analysis of stage II disease from the AVANT phase III randomized trial by the GERCOR group
    De Gramont, A.
    Henriques, J.
    Baruch, B.
    Kim, T. W.
    Martinez-Villacampa, M.
    Gallego-Plazas, J.
    Cervantes, A.
    Shim, K.
    Jonker, D. J.
    Guerin-Meyer, V.
    Mineur, L.
    Banzi, M.
    Dewdney, A.
    Dejthevaporn, T. Sirisingha
    Bloemendal, H. J.
    Roth, A. D.
    Thompson, P.
    Moehler, M.
    Aranda Aguilar, E.
    Andre, T.
    ANNALS OF ONCOLOGY, 2019, 30
  • [24] A SYSTEMATIC REVIEW AND META-ANALYSIS OF ADJUVANT CHEMOTHERAPY FOR STAGE III COLON CANCER
    Lerdkiattikorn, P.
    Chaikledkaew, U.
    Kingkaew, P.
    Teerawattananon, Y.
    VALUE IN HEALTH, 2010, 13 (07) : A503 - A503
  • [25] Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): Updated results of IDEA (International Duration Evaluation of Adjuvant chemotherapy)
    Grothey, A.
    Sobrero, A.
    Meyerhardt, J. A.
    Yoshino, T.
    Paul, J.
    Taieb, J.
    Souglakos, I.
    Kerr, R.
    Labianca, R.
    Shields, A. F.
    Bonnetain, F.
    Yamanaka, T.
    Boukovinas, I.
    Shi, Q.
    Meyers, J. P.
    Niedzwiecki, D.
    Torri, V.
    Sargent, D. J.
    Andre, T.
    Iveson, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [26] The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study
    Liao, Leen
    Tang, Jinghua
    Hong, Zhigang
    Jiang, Wu
    Li, Yuan
    Kong, Lingheng
    Han, Kai
    Hou, Zhenlin
    Zhang, Chenzhi
    Zhou, Chi
    Zhang, Linjie
    Sui, Qiaoqi
    Xiao, Binyi
    Mei, Weijian
    Yu, Jiehai
    Yang, Wanjun
    Pan, Zhizhong
    Ding, Pei-Rong
    BMC CANCER, 2024, 24 (01)
  • [27] The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study
    Leen Liao
    Jinghua Tang
    Zhigang Hong
    Wu Jiang
    Yuan Li
    Lingheng Kong
    Kai Han
    Zhenlin Hou
    Chenzhi Zhang
    Chi Zhou
    Linjie Zhang
    Qiaoqi Sui
    Binyi Xiao
    Weijian Mei
    Jiehai Yu
    Wanjun Yang
    Zhizhong Pan
    Pei-Rong Ding
    BMC Cancer, 24
  • [28] Tumor budding, an important prognostic factor in stage III colon cancer patients treated with oxaliplatin-based chemotherapy
    Basile, D.
    Broudin, C.
    Emile, J-F.
    Falcoz, A.
    Toullec, C.
    Bennouna, J.
    Louvet, C.
    Desrame, J.
    Fratte, S.
    Andre, T.
    Taieb, J.
    Svrcek, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S533 - S533
  • [29] The clinical utility of early follow-up computed tomography in patients with stage II-III colorectal cancer receiving oxaliplatin-based chemotherapy
    Lee, Y.
    Kim, S. Y.
    Kim, J. E.
    Hong, Y. S.
    Kim, T. W.
    ANNALS OF ONCOLOGY, 2018, 29 : 195 - 195
  • [30] Survival outcomes associated with completion of adjuvant oxaliplatin-based chemotherapy for stage III colon cancer: A national population-based study
    Boyle, Jemma M.
    Kuryba, Angela
    Cowling, Thomas E.
    van der Meulen, Jan
    Fearnhead, Nicola S.
    Walker, Kate
    Braun, Michael S.
    Aggarwal, Ajay
    INTERNATIONAL JOURNAL OF CANCER, 2022, 150 (02) : 335 - 346
12345